Logo image of EVAX

EVAXION A/S (EVAX) Stock Fundamental Analysis

NASDAQ:EVAX - Nasdaq - US29970R3030 - ADR - Currency: USD

2.47  -0.01 (-0.4%)

After market: 2.46 -0.01 (-0.4%)

Fundamental Rating

2

Overall EVAX gets a fundamental rating of 2 out of 10. We evaluated EVAX against 555 industry peers in the Biotechnology industry. Both the profitability and financial health of EVAX have multiple concerns. EVAX is quite expensive at the moment. It does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year EVAX has reported negative net income.
In the past year EVAX has reported a negative cash flow from operations.
In the past 5 years EVAX always reported negative net income.
EVAX had a negative operating cash flow in each of the past 5 years.
EVAX Yearly Net Income VS EBIT VS OCF VS FCFEVAX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2018 2019 2020 2021 2022 2023 2024 -5M -10M -15M -20M -25M

1.2 Ratios

EVAX's Return On Assets of -84.65% is on the low side compared to the rest of the industry. EVAX is outperformed by 72.25% of its industry peers.
Industry RankSector Rank
ROA -84.65%
ROE N/A
ROIC N/A
ROA(3y)-120.5%
ROA(5y)-109.62%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
EVAX Yearly ROA, ROE, ROICEVAX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2018 2019 2020 2021 2022 2023 2024 0 200 -200 400 600

1.3 Margins

EVAX does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
EVAX Yearly Profit, Operating, Gross MarginsEVAX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2018 2019 2020 2021 2022 2023 2024 -10K -20K -30K

More info and screens

3

2. Health

2.1 Basic Checks

EVAX does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for EVAX has been increased compared to 1 year ago.
Compared to 5 years ago, EVAX has less shares outstanding
The debt/assets ratio for EVAX has been reduced compared to a year ago.
EVAX Yearly Shares OutstandingEVAX Yearly Shares OutstandingYearly Shares Outstanding 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M
EVAX Yearly Total Debt VS Total AssetsEVAX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M

2.2 Solvency

Based on the Altman-Z score of -3.90, we must say that EVAX is in the distress zone and has some risk of bankruptcy.
The Altman-Z score of EVAX (-3.90) is comparable to the rest of the industry.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -3.9
ROIC/WACCN/A
WACC5.13%
EVAX Yearly LT Debt VS Equity VS FCFEVAX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2018 2019 2020 2021 2022 2023 2024 0 10M -10M 20M -20M 30M

2.3 Liquidity

EVAX has a Current Ratio of 2.01. This indicates that EVAX is financially healthy and has no problem in meeting its short term obligations.
With a Current ratio value of 2.01, EVAX is not doing good in the industry: 75.86% of the companies in the same industry are doing better.
A Quick Ratio of 2.01 indicates that EVAX has no problem at all paying its short term obligations.
EVAX's Quick ratio of 2.01 is on the low side compared to the rest of the industry. EVAX is outperformed by 74.05% of its industry peers.
Industry RankSector Rank
Current Ratio 2.01
Quick Ratio 2.01
EVAX Yearly Current Assets VS Current LiabilitesEVAX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M

More info and screens

4

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 95.02% over the past year.
EVAX shows a strong growth in Revenue. In the last year, the Revenue has grown by 2555.65%.
EPS 1Y (TTM)95.02%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-133.33%
Revenue 1Y (TTM)2555.65%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-100%

3.2 Future

EVAX is expected to show a very negative growth in Earnings Per Share. In the coming years, the EPS will decrease by -31.97% yearly.
Based on estimates for the next years, EVAX will show a very strong growth in Revenue. The Revenue will grow by 61.85% on average per year.
EPS Next Y-511.24%
EPS Next 2Y-90.24%
EPS Next 3Y-56.74%
EPS Next 5Y-31.97%
Revenue Next Year-100%
Revenue Next 2Y-17.57%
Revenue Next 3Y59.75%
Revenue Next 5Y61.85%

3.3 Evolution

EVAX Yearly Revenue VS EstimatesEVAX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2023 2024 2026 2027 2028 2029 2030 2031 2032 20M 40M 60M
EVAX Yearly EPS VS EstimatesEVAX Yearly EPS VS EstimatesYearly EPS VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2031 2032 0 -20 -40 -60

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

EVAX reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year EVAX is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
EVAX Price Earnings VS Forward Price EarningsEVAX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
EVAX Per share dataEVAX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 -0.5 -1 -1.5 -2

4.3 Compensation for Growth

EVAX's earnings are expected to decrease with -56.74% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-90.24%
EPS Next 3Y-56.74%

More info and screens

0

5. Dividend

5.1 Amount

EVAX does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

EVAXION A/S

NASDAQ:EVAX (7/2/2025, 8:00:02 PM)

After market: 2.46 -0.01 (-0.4%)

2.47

-0.01 (-0.4%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)05-27 2025-05-27/bmo
Earnings (Next)08-12 2025-08-12
Inst Owners2.18%
Inst Owner Change43614.2%
Ins Owners0.68%
Ins Owner ChangeN/A
Market Cap15.60M
Analysts82.5
Price Target32.56 (1218.22%)
Short Float %1.03%
Short Ratio0.48
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)92.28%
Min EPS beat(2)86.32%
Max EPS beat(2)98.23%
EPS beat(4)4
Avg EPS beat(4)101.85%
Min EPS beat(4)69.83%
Max EPS beat(4)152.99%
EPS beat(8)7
Avg EPS beat(8)51.25%
EPS beat(12)10
Avg EPS beat(12)39.44%
EPS beat(16)12
Avg EPS beat(16)29.3%
Revenue beat(2)1
Avg Revenue beat(2)42.12%
Min Revenue beat(2)-92.79%
Max Revenue beat(2)177.04%
Revenue beat(4)3
Avg Revenue beat(4)77.43%
Min Revenue beat(4)-92.79%
Max Revenue beat(4)190.35%
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-31.27%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)13.31%
EPS NY rev (3m)-15.45%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-98.12%
Revenue NY rev (1m)-100%
Revenue NY rev (3m)-100%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 4.67
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-1.37
EYN/A
EPS(NY)-1.02
Fwd EYN/A
FCF(TTM)-2.05
FCFYN/A
OCF(TTM)-2.05
OCFYN/A
SpS0.53
BVpS-0.26
TBVpS-0.26
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -84.65%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-120.5%
ROA(5y)-109.62%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0.27
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 0%
Cap/Sales 0%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.01
Quick Ratio 2.01
Altman-Z -3.9
F-Score5
WACC5.13%
ROIC/WACCN/A
Cap/Depr(3y)21.76%
Cap/Depr(5y)127.17%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)95.02%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-133.33%
EPS Next Y-511.24%
EPS Next 2Y-90.24%
EPS Next 3Y-56.74%
EPS Next 5Y-31.97%
Revenue 1Y (TTM)2555.65%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-100%
Revenue Next Year-100%
Revenue Next 2Y-17.57%
Revenue Next 3Y59.75%
Revenue Next 5Y61.85%
EBIT growth 1Y33.63%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year61.67%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y27.21%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y26.86%
OCF growth 3YN/A
OCF growth 5YN/A